Dana Investment Advisors Inc. Increases Stock Position in Blueprint Medicines Co. (NASDAQ:BPMC)

Dana Investment Advisors Inc. boosted its stake in Blueprint Medicines Co. (NASDAQ:BPMC) by 6.2% during the 4th quarter, Holdings Channel reports. The firm owned 39,074 shares of the biotechnology company’s stock after buying an additional 2,282 shares during the quarter. Dana Investment Advisors Inc.’s holdings in Blueprint Medicines were worth $3,408,000 at the end of the most recent reporting period.

Other hedge funds have also bought and sold shares of the company. Quarry LP purchased a new stake in Blueprint Medicines in the 3rd quarter worth $32,000. R Squared Ltd purchased a new stake in shares of Blueprint Medicines during the 4th quarter valued at about $51,000. Covestor Ltd raised its position in shares of Blueprint Medicines by 206.7% during the 3rd quarter. Covestor Ltd now owns 598 shares of the biotechnology company’s stock valued at $55,000 after buying an additional 403 shares in the last quarter. Asset Management One Co. Ltd. purchased a new stake in shares of Blueprint Medicines during the 4th quarter valued at about $88,000. Finally, Van ECK Associates Corp raised its position in shares of Blueprint Medicines by 48.2% during the 4th quarter. Van ECK Associates Corp now owns 1,116 shares of the biotechnology company’s stock valued at $97,000 after buying an additional 363 shares in the last quarter.

Analyst Ratings Changes

Several analysts have recently issued reports on BPMC shares. Piper Sandler upped their target price on shares of Blueprint Medicines from $109.00 to $119.00 and gave the company a “neutral” rating in a research report on Monday, January 27th. Stephens restated an “overweight” rating and set a $140.00 target price on shares of Blueprint Medicines in a research report on Thursday, January 2nd. Scotiabank started coverage on shares of Blueprint Medicines in a research report on Friday. They set a “sector outperform” rating and a $150.00 target price on the stock. Needham & Company LLC restated a “buy” rating and set a $133.00 target price on shares of Blueprint Medicines in a research report on Thursday, February 13th. Finally, JMP Securities reiterated a “market outperform” rating and set a $125.00 price target on shares of Blueprint Medicines in a report on Friday, February 14th. Two equities research analysts have rated the stock with a sell rating, six have given a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Blueprint Medicines has an average rating of “Moderate Buy” and an average target price of $125.21.

Insider Activity

In other news, CEO Kate Haviland sold 1,446 shares of the stock in a transaction that occurred on Tuesday, January 21st. The shares were sold at an average price of $110.24, for a total transaction of $159,407.04. Following the transaction, the chief executive officer now directly owns 149,378 shares in the company, valued at approximately $16,467,430.72. This trade represents a 0.96 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Ariel Hurley sold 1,819 shares of the stock in a transaction that occurred on Thursday, December 12th. The shares were sold at an average price of $93.26, for a total transaction of $169,639.94. Following the transaction, the insider now owns 14,967 shares in the company, valued at approximately $1,395,822.42. This represents a 10.84 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 48,427 shares of company stock worth $4,837,801. Corporate insiders own 4.21% of the company’s stock.

Blueprint Medicines Price Performance

Shares of BPMC stock opened at $87.12 on Friday. The company has a debt-to-equity ratio of 1.15, a current ratio of 2.85 and a quick ratio of 2.80. The company has a market capitalization of $5.57 billion, a P/E ratio of -80.67 and a beta of 0.62. The company’s 50-day simple moving average is $99.43 and its two-hundred day simple moving average is $94.27. Blueprint Medicines Co. has a one year low of $80.68 and a one year high of $121.90.

Blueprint Medicines (NASDAQ:BPMC) last released its quarterly earnings data on Thursday, February 20th. The biotechnology company reported ($0.79) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by ($0.11). Blueprint Medicines had a negative net margin of 13.19% and a negative return on equity of 77.49%. As a group, equities analysts anticipate that Blueprint Medicines Co. will post -1.28 EPS for the current year.

About Blueprint Medicines

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders.